Jason Farrar
Concepts (449)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Leukemia, Myeloid, Acute | 15 | 2024 | 180 | 3.170 |
Why?
| Anemia, Diamond-Blackfan | 13 | 2024 | 13 | 2.730 |
Why?
| Mutation | 15 | 2023 | 1275 | 1.730 |
Why?
| Pain Measurement | 17 | 2023 | 271 | 1.710 |
Why?
| Clinical Trials as Topic | 18 | 2018 | 488 | 1.540 |
Why?
| Ribosomal Proteins | 9 | 2021 | 23 | 1.490 |
Why?
| Analgesics | 12 | 2018 | 117 | 1.350 |
Why?
| Pain | 14 | 2023 | 386 | 1.310 |
Why?
| Midazolam | 1 | 2024 | 37 | 0.910 |
Why?
| Hypnotics and Sedatives | 1 | 2024 | 75 | 0.870 |
Why?
| Humans | 101 | 2025 | 50419 | 0.860 |
Why?
| Electroacupuncture | 4 | 2015 | 6 | 0.840 |
Why?
| Neurosurgical Procedures | 1 | 2024 | 126 | 0.830 |
Why?
| Breast Neoplasms | 5 | 2021 | 1198 | 0.830 |
Why?
| Gene Expression Profiling | 6 | 2023 | 1020 | 0.800 |
Why?
| Wounds and Injuries | 2 | 2025 | 288 | 0.760 |
Why?
| Rhabdomyosarcoma, Alveolar | 1 | 2021 | 8 | 0.750 |
Why?
| Li-Fraumeni Syndrome | 1 | 2021 | 11 | 0.750 |
Why?
| Testosterone | 6 | 2018 | 145 | 0.740 |
Why?
| Enoxaparin | 1 | 2021 | 31 | 0.720 |
Why?
| Female | 45 | 2025 | 27053 | 0.690 |
Why?
| Aged | 29 | 2025 | 9738 | 0.670 |
Why?
| Venous Thromboembolism | 1 | 2021 | 74 | 0.670 |
Why?
| Chronic Pain | 6 | 2023 | 183 | 0.660 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2021 | 212 | 0.660 |
Why?
| Male | 45 | 2025 | 25866 | 0.640 |
Why?
| Diabetic Neuropathies | 3 | 2016 | 57 | 0.630 |
Why?
| Critical Illness | 4 | 2025 | 302 | 0.630 |
Why?
| Neuralgia | 3 | 2018 | 67 | 0.620 |
Why?
| Body Weight | 1 | 2021 | 517 | 0.620 |
Why?
| Cyclohexanecarboxylic Acids | 2 | 2015 | 20 | 0.600 |
Why?
| Amines | 2 | 2015 | 42 | 0.590 |
Why?
| gamma-Aminobutyric Acid | 2 | 2015 | 64 | 0.580 |
Why?
| Fatigue | 4 | 2019 | 127 | 0.550 |
Why?
| RNA Processing, Post-Transcriptional | 3 | 2014 | 23 | 0.550 |
Why?
| Neuralgia, Postherpetic | 2 | 2014 | 3 | 0.540 |
Why?
| Middle Aged | 24 | 2025 | 12579 | 0.530 |
Why?
| Treatment Outcome | 21 | 2023 | 5265 | 0.530 |
Why?
| Research Design | 8 | 2016 | 348 | 0.530 |
Why?
| Child, Preschool | 20 | 2021 | 3953 | 0.530 |
Why?
| Acute Pain | 2 | 2016 | 11 | 0.510 |
Why?
| Adult | 23 | 2025 | 13561 | 0.490 |
Why?
| Hot Flashes | 1 | 2015 | 7 | 0.490 |
Why?
| Spinal Stenosis | 1 | 2015 | 13 | 0.490 |
Why?
| GATA1 Transcription Factor | 2 | 2017 | 7 | 0.480 |
Why?
| Hormone Replacement Therapy | 6 | 2018 | 33 | 0.480 |
Why?
| Chemotherapy, Adjuvant | 1 | 2015 | 119 | 0.480 |
Why?
| Infant | 17 | 2021 | 3648 | 0.470 |
Why?
| Oncogene Proteins, Fusion | 4 | 2024 | 57 | 0.470 |
Why?
| RNA, Ribosomal | 1 | 2014 | 17 | 0.460 |
Why?
| RNA Precursors | 1 | 2014 | 8 | 0.460 |
Why?
| Lumbar Vertebrae | 1 | 2015 | 102 | 0.460 |
Why?
| Codon, Initiator | 1 | 2014 | 1 | 0.450 |
Why?
| Child | 25 | 2025 | 6931 | 0.450 |
Why?
| Bone Neoplasms | 2 | 2023 | 178 | 0.440 |
Why?
| Meningitis, Cryptococcal | 2 | 2010 | 10 | 0.440 |
Why?
| Point Mutation | 1 | 2014 | 61 | 0.440 |
Why?
| Pain Management | 6 | 2016 | 180 | 0.440 |
Why?
| Prognosis | 6 | 2024 | 1974 | 0.380 |
Why?
| Molar, Third | 1 | 2011 | 4 | 0.380 |
Why?
| Tooth Extraction | 1 | 2011 | 7 | 0.380 |
Why?
| Survivors | 2 | 2015 | 126 | 0.370 |
Why?
| Cryptococcus neoformans | 2 | 2010 | 26 | 0.370 |
Why?
| Tomography, Emission-Computed, Single-Photon | 1 | 2011 | 52 | 0.370 |
Why?
| Amplified Fragment Length Polymorphism Analysis | 1 | 2010 | 3 | 0.360 |
Why?
| Mycological Typing Techniques | 1 | 2010 | 3 | 0.360 |
Why?
| Cerebrovascular Circulation | 1 | 2011 | 132 | 0.350 |
Why?
| Sexual Behavior | 3 | 2016 | 116 | 0.350 |
Why?
| DNA, Fungal | 1 | 2010 | 44 | 0.350 |
Why?
| Gene Deletion | 1 | 2011 | 260 | 0.350 |
Why?
| Brain Mapping | 1 | 2011 | 224 | 0.340 |
Why?
| Pain, Postoperative | 1 | 2011 | 163 | 0.340 |
Why?
| Arthralgia | 3 | 2014 | 45 | 0.330 |
Why?
| Adolescent | 16 | 2025 | 6453 | 0.330 |
Why?
| Practice Guidelines as Topic | 4 | 2015 | 473 | 0.330 |
Why?
| Drug Resistance, Bacterial | 2 | 2010 | 71 | 0.320 |
Why?
| Biomedical Research | 3 | 2015 | 243 | 0.320 |
Why?
| Randomized Controlled Trials as Topic | 6 | 2023 | 567 | 0.320 |
Why?
| Dysentery, Bacillary | 1 | 2009 | 2 | 0.310 |
Why?
| Shigella | 1 | 2009 | 4 | 0.310 |
Why?
| Acupuncture Therapy | 1 | 2009 | 4 | 0.310 |
Why?
| Cephalosporins | 1 | 2009 | 39 | 0.310 |
Why?
| Intensive Care Units | 3 | 2025 | 228 | 0.310 |
Why?
| Osteoarthritis, Knee | 2 | 2023 | 98 | 0.300 |
Why?
| Dogs | 1 | 2008 | 185 | 0.300 |
Why?
| Vietnam | 7 | 2010 | 27 | 0.300 |
Why?
| Disability Evaluation | 3 | 2019 | 92 | 0.290 |
Why?
| Radiotherapy | 1 | 2009 | 125 | 0.290 |
Why?
| Double-Blind Method | 7 | 2023 | 710 | 0.290 |
Why?
| Quality of Life | 8 | 2019 | 850 | 0.280 |
Why?
| Severity of Illness Index | 7 | 2024 | 976 | 0.280 |
Why?
| Young Adult | 11 | 2025 | 4075 | 0.280 |
Why?
| DNA Methylation | 6 | 2023 | 548 | 0.280 |
Why?
| Health Status | 2 | 2017 | 298 | 0.270 |
Why?
| Sleep Initiation and Maintenance Disorders | 1 | 2007 | 43 | 0.270 |
Why?
| Anti-Inflammatory Agents | 2 | 2019 | 165 | 0.270 |
Why?
| Stress, Psychological | 2 | 2014 | 268 | 0.270 |
Why?
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 2 | 2017 | 6 | 0.260 |
Why?
| Prospective Studies | 6 | 2024 | 2378 | 0.260 |
Why?
| Disease Models, Animal | 3 | 2021 | 1431 | 0.260 |
Why?
| Aromatase Inhibitors | 3 | 2014 | 17 | 0.250 |
Why?
| Pain, Intractable | 3 | 2011 | 9 | 0.250 |
Why?
| Polymorphism, Single Nucleotide | 4 | 2013 | 468 | 0.250 |
Why?
| Anti-Bacterial Agents | 2 | 2025 | 751 | 0.250 |
Why?
| Aged, 80 and over | 7 | 2024 | 3233 | 0.240 |
Why?
| Exocrine Pancreatic Insufficiency | 1 | 2025 | 4 | 0.240 |
Why?
| Lipomatosis | 1 | 2025 | 6 | 0.240 |
Why?
| Bone Marrow Diseases | 1 | 2025 | 11 | 0.240 |
Why?
| Kidney Function Tests | 1 | 2025 | 52 | 0.240 |
Why?
| Oligonucleotide Array Sequence Analysis | 3 | 2011 | 400 | 0.240 |
Why?
| Age Factors | 4 | 2021 | 1118 | 0.240 |
Why?
| Creatinine | 1 | 2025 | 142 | 0.230 |
Why?
| Walking | 2 | 2016 | 100 | 0.230 |
Why?
| Pneumonia, Ventilator-Associated | 1 | 2025 | 21 | 0.230 |
Why?
| Nutritional Support | 1 | 2024 | 35 | 0.230 |
Why?
| Drug Resistance, Multiple, Bacterial | 1 | 2025 | 63 | 0.230 |
Why?
| Lymphoma | 1 | 2025 | 66 | 0.230 |
Why?
| Retrospective Studies | 8 | 2025 | 6274 | 0.220 |
Why?
| Terminal Care | 1 | 2024 | 46 | 0.220 |
Why?
| Cystitis, Interstitial | 1 | 2023 | 11 | 0.220 |
Why?
| Hemophilia A | 1 | 2024 | 25 | 0.220 |
Why?
| Neurodegenerative Diseases | 1 | 2024 | 74 | 0.210 |
Why?
| Gene Rearrangement | 1 | 2024 | 63 | 0.210 |
Why?
| Case-Control Studies | 4 | 2017 | 1152 | 0.210 |
Why?
| Neuromuscular Blockade | 1 | 2023 | 15 | 0.210 |
Why?
| Encephalitis, Japanese | 1 | 2003 | 2 | 0.210 |
Why?
| Cell Cycle Proteins | 2 | 2021 | 163 | 0.210 |
Why?
| Chromatography, High Pressure Liquid | 1 | 2024 | 326 | 0.210 |
Why?
| Consensus | 1 | 2024 | 159 | 0.210 |
Why?
| Tandem Mass Spectrometry | 1 | 2024 | 238 | 0.210 |
Why?
| Osteosarcoma | 1 | 2023 | 45 | 0.210 |
Why?
| Interferon-alpha | 1 | 2003 | 48 | 0.200 |
Why?
| Viruses | 2 | 2015 | 21 | 0.200 |
Why?
| Medicare | 1 | 2024 | 247 | 0.200 |
Why?
| Enteral Nutrition | 1 | 2023 | 149 | 0.200 |
Why?
| Chromosome Aberrations | 3 | 2017 | 279 | 0.200 |
Why?
| Azacitidine | 2 | 2023 | 34 | 0.190 |
Why?
| Blood Glucose | 1 | 2024 | 447 | 0.190 |
Why?
| Leukemia, Myelomonocytic, Juvenile | 1 | 2022 | 14 | 0.190 |
Why?
| Incidence | 2 | 2025 | 1027 | 0.190 |
Why?
| Antiviral Agents | 1 | 2003 | 171 | 0.180 |
Why?
| Cross-Sectional Studies | 4 | 2019 | 1601 | 0.180 |
Why?
| Drug Dosage Calculations | 1 | 2021 | 11 | 0.180 |
Why?
| Diabetes Mellitus | 1 | 2024 | 281 | 0.180 |
Why?
| Neoplasms, Second Primary | 1 | 2022 | 74 | 0.180 |
Why?
| Co-Repressor Proteins | 1 | 2021 | 17 | 0.180 |
Why?
| Neoplasms | 2 | 2009 | 1248 | 0.180 |
Why?
| Androgens | 2 | 2018 | 71 | 0.180 |
Why?
| Erythrocyte Transfusion | 1 | 2021 | 52 | 0.180 |
Why?
| Gene Regulatory Networks | 1 | 2021 | 106 | 0.180 |
Why?
| Placebos | 4 | 2016 | 87 | 0.180 |
Why?
| Chromosomal Proteins, Non-Histone | 1 | 2021 | 36 | 0.180 |
Why?
| Injury Severity Score | 1 | 2021 | 165 | 0.170 |
Why?
| B-Lymphocytes | 1 | 2021 | 171 | 0.170 |
Why?
| Kidney | 1 | 2025 | 690 | 0.170 |
Why?
| Registries | 2 | 2018 | 565 | 0.170 |
Why?
| Chromatin | 1 | 2021 | 133 | 0.170 |
Why?
| Leucine | 1 | 2020 | 118 | 0.170 |
Why?
| Evidence-Based Medicine | 3 | 2011 | 254 | 0.160 |
Why?
| Blood Transfusion | 1 | 2020 | 123 | 0.160 |
Why?
| MicroRNAs | 2 | 2021 | 345 | 0.160 |
Why?
| Systemic Vasculitis | 1 | 2019 | 2 | 0.160 |
Why?
| Dose-Response Relationship, Drug | 2 | 2021 | 1369 | 0.160 |
Why?
| Ribosomes | 2 | 2009 | 21 | 0.160 |
Why?
| Recurrence | 2 | 2022 | 657 | 0.150 |
Why?
| Sex Factors | 1 | 2021 | 718 | 0.150 |
Why?
| Controlled Clinical Trials as Topic | 1 | 2018 | 22 | 0.150 |
Why?
| Research Report | 1 | 2018 | 16 | 0.150 |
Why?
| DNA-Binding Proteins | 1 | 2021 | 410 | 0.150 |
Why?
| Risk Factors | 3 | 2025 | 3712 | 0.150 |
Why?
| Anxiety | 2 | 2023 | 285 | 0.140 |
Why?
| Feasibility Studies | 3 | 2020 | 389 | 0.140 |
Why?
| Induction Chemotherapy | 1 | 2017 | 59 | 0.140 |
Why?
| Sensory Thresholds | 1 | 2017 | 18 | 0.140 |
Why?
| Ribosome Subunits, Large, Eukaryotic | 2 | 2014 | 2 | 0.140 |
Why?
| Agammaglobulinemia | 1 | 1996 | 9 | 0.140 |
Why?
| X Chromosome | 1 | 1996 | 12 | 0.140 |
Why?
| United States | 5 | 2024 | 5005 | 0.130 |
Why?
| Genome, Human | 2 | 2021 | 108 | 0.130 |
Why?
| Infant, Newborn | 4 | 2023 | 2752 | 0.130 |
Why?
| Anemia | 1 | 2017 | 67 | 0.130 |
Why?
| Phenotype | 3 | 2021 | 736 | 0.130 |
Why?
| HIV Infections | 2 | 2010 | 347 | 0.130 |
Why?
| Receptors, Colony-Stimulating Factor | 1 | 2016 | 1 | 0.130 |
Why?
| Sexual Dysfunction, Physiological | 1 | 2016 | 17 | 0.130 |
Why?
| Hemoglobins | 1 | 2017 | 112 | 0.130 |
Why?
| CCAAT-Enhancer-Binding Proteins | 1 | 2016 | 14 | 0.130 |
Why?
| Cell Proliferation | 4 | 2021 | 980 | 0.130 |
Why?
| Animals | 9 | 2023 | 13063 | 0.130 |
Why?
| Inservice Training | 1 | 2016 | 34 | 0.130 |
Why?
| Neutropenia | 1 | 1996 | 116 | 0.130 |
Why?
| Health Planning Guidelines | 2 | 2007 | 15 | 0.130 |
Why?
| Low Back Pain | 1 | 2016 | 28 | 0.130 |
Why?
| Consensus Development Conferences as Topic | 1 | 2015 | 13 | 0.120 |
Why?
| Genotype | 3 | 2013 | 525 | 0.120 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 568 | 0.120 |
Why?
| DNA Copy Number Variations | 1 | 2016 | 109 | 0.120 |
Why?
| Needles | 1 | 2015 | 25 | 0.120 |
Why?
| Time Factors | 5 | 2015 | 2933 | 0.120 |
Why?
| Influenza A Virus, H5N1 Subtype | 1 | 2015 | 1 | 0.120 |
Why?
| Exercise Test | 1 | 2015 | 131 | 0.120 |
Why?
| Hypopituitarism | 1 | 2014 | 17 | 0.120 |
Why?
| Placebo Effect | 1 | 2014 | 17 | 0.120 |
Why?
| Intention to Treat Analysis | 1 | 2014 | 28 | 0.120 |
Why?
| Pilot Projects | 2 | 2020 | 694 | 0.120 |
Why?
| Ribosome Subunits, Small, Eukaryotic | 1 | 2014 | 2 | 0.120 |
Why?
| Gonadal Steroid Hormones | 1 | 2014 | 41 | 0.120 |
Why?
| K562 Cells | 1 | 2014 | 40 | 0.110 |
Why?
| Transcription Factors | 3 | 2024 | 561 | 0.110 |
Why?
| Virus Diseases | 1 | 2015 | 42 | 0.110 |
Why?
| Analgesics, Opioid | 2 | 2012 | 577 | 0.110 |
Why?
| Exercise | 1 | 2018 | 513 | 0.110 |
Why?
| Chromosome Mapping | 3 | 2011 | 143 | 0.110 |
Why?
| Skin | 1 | 2017 | 382 | 0.110 |
Why?
| Leukemia, Myeloid | 1 | 2014 | 44 | 0.110 |
Why?
| Molecular Epidemiology | 2 | 2010 | 34 | 0.110 |
Why?
| Influenza, Human | 1 | 2015 | 86 | 0.110 |
Why?
| Respiratory Tract Infections | 1 | 2015 | 83 | 0.110 |
Why?
| Anemia, Macrocytic | 1 | 2013 | 2 | 0.110 |
Why?
| Motor Activity | 1 | 2014 | 224 | 0.110 |
Why?
| Cluster Analysis | 2 | 2010 | 209 | 0.110 |
Why?
| Prescription Drug Misuse | 1 | 2013 | 34 | 0.110 |
Why?
| Cytogenetic Analysis | 1 | 2013 | 74 | 0.110 |
Why?
| Base Sequence | 3 | 2010 | 622 | 0.100 |
Why?
| Aging | 1 | 2018 | 692 | 0.100 |
Why?
| Endpoint Determination | 2 | 2013 | 26 | 0.100 |
Why?
| Depression | 2 | 2016 | 577 | 0.100 |
Why?
| Prevalence | 3 | 2018 | 967 | 0.100 |
Why?
| Self Report | 1 | 2014 | 206 | 0.100 |
Why?
| RNA, Messenger | 4 | 2021 | 1085 | 0.100 |
Why?
| Genomics | 1 | 2014 | 238 | 0.100 |
Why?
| Heart Defects, Congenital | 1 | 2018 | 603 | 0.100 |
Why?
| Neurology | 1 | 2012 | 42 | 0.100 |
Why?
| Chromosome Deletion | 2 | 2013 | 134 | 0.100 |
Why?
| Pain Perception | 1 | 2011 | 5 | 0.100 |
Why?
| Organotechnetium Compounds | 1 | 2011 | 7 | 0.090 |
Why?
| Pennsylvania | 1 | 2011 | 36 | 0.090 |
Why?
| Haploinsufficiency | 1 | 2011 | 14 | 0.090 |
Why?
| Mosaicism | 1 | 2011 | 18 | 0.090 |
Why?
| Libido | 3 | 2016 | 9 | 0.090 |
Why?
| Genotyping Techniques | 1 | 2011 | 19 | 0.090 |
Why?
| Blotting, Northern | 1 | 2011 | 109 | 0.090 |
Why?
| Cysteine | 1 | 2011 | 50 | 0.090 |
Why?
| Analgesia | 1 | 2011 | 13 | 0.090 |
Why?
| Microbial Sensitivity Tests | 2 | 2010 | 268 | 0.090 |
Why?
| RNA, Small Interfering | 2 | 2008 | 208 | 0.090 |
Why?
| Encephalitis, Viral | 1 | 2010 | 6 | 0.090 |
Why?
| Neoplastic Stem Cells | 2 | 2022 | 97 | 0.090 |
Why?
| Genome-Wide Association Study | 1 | 2011 | 163 | 0.090 |
Why?
| Radiopharmaceuticals | 1 | 2011 | 202 | 0.090 |
Why?
| Typhoid Fever | 1 | 2010 | 2 | 0.090 |
Why?
| Salmonella typhi | 1 | 2010 | 3 | 0.090 |
Why?
| Dengue | 1 | 2010 | 3 | 0.090 |
Why?
| Viremia | 1 | 2010 | 21 | 0.090 |
Why?
| Bacterial Typing Techniques | 1 | 2010 | 34 | 0.080 |
Why?
| Daunorubicin | 2 | 2022 | 11 | 0.080 |
Why?
| Reproducibility of Results | 2 | 2016 | 1181 | 0.080 |
Why?
| WT1 Proteins | 1 | 2009 | 4 | 0.080 |
Why?
| Cytarabine | 2 | 2022 | 37 | 0.080 |
Why?
| Antibodies, Viral | 1 | 2010 | 93 | 0.080 |
Why?
| DNA, Bacterial | 1 | 2010 | 165 | 0.080 |
Why?
| Outpatients | 2 | 2024 | 121 | 0.080 |
Why?
| Viral Nonstructural Proteins | 1 | 2010 | 58 | 0.080 |
Why?
| Chronic Disease | 5 | 2011 | 573 | 0.080 |
Why?
| Cohort Studies | 2 | 2016 | 1451 | 0.080 |
Why?
| Guidelines as Topic | 1 | 2009 | 110 | 0.080 |
Why?
| Brain | 1 | 2017 | 1318 | 0.080 |
Why?
| Chromosomes, Human, Pair 3 | 1 | 2008 | 18 | 0.070 |
Why?
| Pedigree | 1 | 2008 | 119 | 0.070 |
Why?
| Saccharomyces cerevisiae Proteins | 1 | 2009 | 142 | 0.070 |
Why?
| Opioid-Related Disorders | 1 | 2012 | 392 | 0.070 |
Why?
| Social Participation | 2 | 2019 | 5 | 0.070 |
Why?
| Chromosomes, Human, Pair 6 | 1 | 2007 | 14 | 0.070 |
Why?
| Wilms Tumor | 1 | 2007 | 18 | 0.070 |
Why?
| Genes, Tumor Suppressor | 1 | 2007 | 73 | 0.070 |
Why?
| Oxycodone | 1 | 2007 | 27 | 0.070 |
Why?
| Amino Acid Sequence | 1 | 2008 | 575 | 0.070 |
Why?
| Health Care Surveys | 1 | 2007 | 208 | 0.070 |
Why?
| Molecular Sequence Data | 1 | 2008 | 760 | 0.070 |
Why?
| Ubiquitin-Protein Ligases | 1 | 2007 | 93 | 0.070 |
Why?
| Focus Groups | 2 | 2023 | 193 | 0.070 |
Why?
| DNA Helicases | 1 | 2008 | 147 | 0.070 |
Why?
| Mice | 4 | 2023 | 5659 | 0.070 |
Why?
| Cell Differentiation | 2 | 2021 | 640 | 0.060 |
Why?
| Models, Biological | 1 | 2009 | 717 | 0.060 |
Why?
| Kidney Neoplasms | 1 | 2007 | 174 | 0.060 |
Why?
| Cell Line | 1 | 2008 | 997 | 0.060 |
Why?
| Comorbidity | 1 | 2007 | 621 | 0.060 |
Why?
| Graft vs Host Disease | 1 | 2005 | 85 | 0.060 |
Why?
| Tacrolimus | 1 | 2005 | 54 | 0.060 |
Why?
| Transcriptome | 2 | 2017 | 314 | 0.060 |
Why?
| Insulin, Isophane | 1 | 2024 | 1 | 0.060 |
Why?
| DNA | 1 | 2008 | 534 | 0.060 |
Why?
| Glomerular Filtration Rate | 1 | 2025 | 119 | 0.060 |
Why?
| Autoimmune Diseases | 1 | 2005 | 78 | 0.060 |
Why?
| Patient Acceptance of Health Care | 2 | 2024 | 342 | 0.060 |
Why?
| Follow-Up Studies | 2 | 2020 | 2231 | 0.060 |
Why?
| Erectile Dysfunction | 2 | 2016 | 90 | 0.060 |
Why?
| Amyotrophic Lateral Sclerosis | 1 | 2024 | 34 | 0.060 |
Why?
| Nucleosome Assembly Protein 1 | 1 | 2024 | 1 | 0.060 |
Why?
| Hospice Care | 1 | 2024 | 27 | 0.060 |
Why?
| Minor Histocompatibility Antigens | 1 | 2024 | 17 | 0.060 |
Why?
| Hyperglycemia | 1 | 2024 | 81 | 0.060 |
Why?
| Factor VIII | 1 | 2024 | 23 | 0.060 |
Why?
| Myeloid-Lymphoid Leukemia Protein | 1 | 2024 | 14 | 0.060 |
Why?
| Proto-Oncogenes | 1 | 2024 | 27 | 0.060 |
Why?
| DEAD-box RNA Helicases | 1 | 2024 | 33 | 0.050 |
Why?
| Retinoblastoma-Binding Protein 2 | 1 | 2023 | 6 | 0.050 |
Why?
| Real-Time Polymerase Chain Reaction | 2 | 2015 | 179 | 0.050 |
Why?
| Nuclear Pore Complex Proteins | 1 | 2023 | 11 | 0.050 |
Why?
| Proto-Oncogene Proteins c-ret | 1 | 2024 | 32 | 0.050 |
Why?
| Health Care Costs | 1 | 2024 | 171 | 0.050 |
Why?
| Autoantibodies | 1 | 2024 | 114 | 0.050 |
Why?
| Trauma Centers | 1 | 2025 | 199 | 0.050 |
Why?
| CpG Islands | 1 | 2023 | 107 | 0.050 |
Why?
| Hypoglycemic Agents | 1 | 2024 | 174 | 0.050 |
Why?
| Ambulatory Care | 1 | 2024 | 243 | 0.050 |
Why?
| Treatment Failure | 1 | 2003 | 120 | 0.050 |
Why?
| Apoptosis | 1 | 2008 | 1092 | 0.050 |
Why?
| Computational Biology | 1 | 2024 | 194 | 0.050 |
Why?
| Disease Management | 1 | 2024 | 179 | 0.050 |
Why?
| Hemorrhage | 1 | 2024 | 195 | 0.050 |
Why?
| Predictive Value of Tests | 1 | 2025 | 924 | 0.050 |
Why?
| Insulin | 1 | 2024 | 464 | 0.050 |
Why?
| Vaccination | 1 | 2024 | 275 | 0.050 |
Why?
| Algorithms | 2 | 2017 | 624 | 0.050 |
Why?
| Parkinson Disease | 1 | 2024 | 161 | 0.050 |
Why?
| Proto-Oncogene Proteins c-cbl | 1 | 2022 | 3 | 0.050 |
Why?
| Core Binding Factor beta Subunit | 1 | 2021 | 3 | 0.050 |
Why?
| Blood Coagulation | 1 | 2002 | 59 | 0.050 |
Why?
| Myosin Heavy Chains | 1 | 2021 | 20 | 0.050 |
Why?
| Longitudinal Studies | 2 | 2019 | 732 | 0.050 |
Why?
| RNA | 1 | 2022 | 164 | 0.050 |
Why?
| Recombinant Proteins | 1 | 2003 | 477 | 0.050 |
Why?
| Qualitative Research | 1 | 2023 | 351 | 0.050 |
Why?
| Gene Expression Regulation, Leukemic | 1 | 2021 | 29 | 0.040 |
Why?
| Enhancer Elements, Genetic | 1 | 2021 | 57 | 0.040 |
Why?
| Acetylation | 1 | 2021 | 94 | 0.040 |
Why?
| Alzheimer Disease | 1 | 2024 | 316 | 0.040 |
Why?
| RNA-Binding Proteins | 1 | 2021 | 116 | 0.040 |
Why?
| Trans-Activators | 1 | 2021 | 135 | 0.040 |
Why?
| Emergency Service, Hospital | 1 | 2024 | 489 | 0.040 |
Why?
| Genetic Association Studies | 1 | 2021 | 118 | 0.040 |
Why?
| HEK293 Cells | 1 | 2021 | 209 | 0.040 |
Why?
| Mice, Inbred BALB C | 1 | 2021 | 293 | 0.040 |
Why?
| Up-Regulation | 1 | 2021 | 446 | 0.040 |
Why?
| Cell Transformation, Neoplastic | 1 | 2021 | 182 | 0.040 |
Why?
| Receptors, GABA-A | 1 | 2019 | 12 | 0.040 |
Why?
| Pandemics | 1 | 2024 | 553 | 0.040 |
Why?
| Risk Assessment | 2 | 2015 | 1268 | 0.040 |
Why?
| Oxidative Stress | 1 | 2024 | 770 | 0.040 |
Why?
| Cell Line, Tumor | 1 | 2023 | 1393 | 0.040 |
Why?
| Hematopoietic Stem Cells | 1 | 2021 | 197 | 0.040 |
Why?
| Protein Binding | 1 | 2021 | 648 | 0.040 |
Why?
| Hematopoietic Stem Cell Transplantation | 1 | 2024 | 580 | 0.040 |
Why?
| Histones | 1 | 2021 | 294 | 0.040 |
Why?
| Emotions | 2 | 2014 | 167 | 0.040 |
Why?
| Combined Modality Therapy | 1 | 2020 | 640 | 0.040 |
Why?
| Patient Selection | 2 | 2010 | 257 | 0.040 |
Why?
| Etoposide | 1 | 2017 | 77 | 0.040 |
Why?
| Drug Administration Routes | 1 | 2017 | 10 | 0.030 |
Why?
| Erythroid Cells | 1 | 2017 | 5 | 0.030 |
Why?
| Genes, Dominant | 1 | 2017 | 19 | 0.030 |
Why?
| Erythropoiesis | 1 | 2017 | 15 | 0.030 |
Why?
| Genes, X-Linked | 1 | 2017 | 7 | 0.030 |
Why?
| Drug Monitoring | 1 | 2017 | 81 | 0.030 |
Why?
| Models, Genetic | 1 | 2017 | 166 | 0.030 |
Why?
| Protein-Tyrosine Kinases | 1 | 1996 | 85 | 0.030 |
Why?
| Cognition | 1 | 2019 | 342 | 0.030 |
Why?
| Statistics as Topic | 1 | 2016 | 86 | 0.030 |
Why?
| Prostate-Specific Antigen | 1 | 2016 | 44 | 0.030 |
Why?
| Basic Reproduction Number | 1 | 2015 | 1 | 0.030 |
Why?
| Reference Values | 1 | 2016 | 302 | 0.030 |
Why?
| Promoter Regions, Genetic | 1 | 2017 | 455 | 0.030 |
Why?
| Meteorological Concepts | 1 | 2015 | 1 | 0.030 |
Why?
| Congresses as Topic | 1 | 2015 | 47 | 0.030 |
Why?
| Pharynx | 1 | 2015 | 31 | 0.030 |
Why?
| Family Health | 1 | 2015 | 76 | 0.030 |
Why?
| China | 1 | 2015 | 91 | 0.030 |
Why?
| Androstadienes | 1 | 2014 | 11 | 0.030 |
Why?
| DNA, Viral | 1 | 2015 | 134 | 0.030 |
Why?
| Nitriles | 1 | 2014 | 52 | 0.030 |
Why?
| Sample Size | 1 | 2014 | 39 | 0.030 |
Why?
| Epigenesis, Genetic | 1 | 2017 | 371 | 0.030 |
Why?
| Publishing | 1 | 2014 | 40 | 0.030 |
Why?
| Child Health Services | 1 | 2015 | 78 | 0.030 |
Why?
| Methylation | 1 | 2014 | 117 | 0.030 |
Why?
| Gait | 1 | 2014 | 89 | 0.030 |
Why?
| Acupuncture Points | 1 | 2013 | 3 | 0.030 |
Why?
| Population | 1 | 2013 | 9 | 0.030 |
Why?
| Triazoles | 1 | 2014 | 113 | 0.030 |
Why?
| Clinical Trials, Phase III as Topic | 1 | 2013 | 47 | 0.030 |
Why?
| Chromosomes, Human, Pair 5 | 1 | 2013 | 15 | 0.030 |
Why?
| Waiting Lists | 1 | 2013 | 59 | 0.030 |
Why?
| Cells, Cultured | 1 | 2017 | 1563 | 0.030 |
Why?
| Substance Abuse Detection | 1 | 2013 | 92 | 0.030 |
Why?
| Terminology as Topic | 1 | 2013 | 67 | 0.030 |
Why?
| Models, Statistical | 1 | 2014 | 224 | 0.030 |
Why?
| Risk | 1 | 2013 | 325 | 0.030 |
Why?
| Immunologic Factors | 1 | 2013 | 113 | 0.020 |
Why?
| Internationality | 1 | 2012 | 39 | 0.020 |
Why?
| Socioeconomic Factors | 1 | 2013 | 591 | 0.020 |
Why?
| Thalidomide | 1 | 2013 | 375 | 0.020 |
Why?
| Virology | 1 | 2010 | 6 | 0.020 |
Why?
| Coma | 1 | 2010 | 16 | 0.020 |
Why?
| Cryptococcus gattii | 1 | 2010 | 1 | 0.020 |
Why?
| Flucytosine | 1 | 2010 | 14 | 0.020 |
Why?
| DNA Gyrase | 1 | 2010 | 4 | 0.020 |
Why?
| Nepal | 1 | 2010 | 11 | 0.020 |
Why?
| Reagent Kits, Diagnostic | 1 | 2010 | 16 | 0.020 |
Why?
| Immunoassay | 1 | 2010 | 20 | 0.020 |
Why?
| High-Throughput Screening Assays | 1 | 2010 | 35 | 0.020 |
Why?
| Amphotericin B | 1 | 2010 | 110 | 0.020 |
Why?
| Haplotypes | 1 | 2010 | 83 | 0.020 |
Why?
| RNA, Viral | 1 | 2010 | 107 | 0.020 |
Why?
| Point-of-Care Systems | 1 | 2010 | 58 | 0.020 |
Why?
| Random Allocation | 1 | 2010 | 284 | 0.020 |
Why?
| Drug Administration Schedule | 1 | 2010 | 373 | 0.020 |
Why?
| Disease-Free Survival | 1 | 2009 | 439 | 0.020 |
Why?
| Retroviridae | 1 | 2008 | 9 | 0.020 |
Why?
| Probability Theory | 1 | 2008 | 2 | 0.020 |
Why?
| Anaerobiosis | 1 | 2008 | 19 | 0.020 |
Why?
| Transduction, Genetic | 1 | 2008 | 45 | 0.020 |
Why?
| Least-Squares Analysis | 1 | 2008 | 39 | 0.020 |
Why?
| Gene Knockdown Techniques | 1 | 2008 | 104 | 0.020 |
Why?
| Sensitivity and Specificity | 1 | 2010 | 855 | 0.020 |
Why?
| Ankyrin Repeat | 1 | 2007 | 2 | 0.020 |
Why?
| Antifungal Agents | 1 | 2010 | 342 | 0.020 |
Why?
| Mice, Mutant Strains | 1 | 2007 | 69 | 0.020 |
Why?
| Pain Clinics | 1 | 2007 | 4 | 0.020 |
Why?
| Signal Transduction | 1 | 2014 | 1608 | 0.020 |
Why?
| Delayed-Action Preparations | 1 | 2007 | 55 | 0.020 |
Why?
| Survival Rate | 1 | 2009 | 906 | 0.020 |
Why?
| Bacterial Proteins | 1 | 2010 | 351 | 0.020 |
Why?
| Multivariate Analysis | 1 | 2008 | 583 | 0.020 |
Why?
| Fibroblasts | 1 | 2008 | 338 | 0.020 |
Why?
| Activities of Daily Living | 1 | 2007 | 175 | 0.020 |
Why?
| Absorption | 1 | 2005 | 22 | 0.020 |
Why?
| Patient Satisfaction | 1 | 2007 | 276 | 0.020 |
Why?
| Analysis of Variance | 1 | 2007 | 549 | 0.020 |
Why?
| Oxygen | 1 | 2008 | 319 | 0.020 |
Why?
| Administration, Topical | 1 | 2005 | 67 | 0.020 |
Why?
| Mental Health | 1 | 2007 | 225 | 0.010 |
Why?
| Bone Marrow Transplantation | 1 | 2005 | 135 | 0.010 |
Why?
| Skin Diseases | 1 | 2005 | 126 | 0.010 |
Why?
| Genetic Predisposition to Disease | 1 | 2007 | 507 | 0.010 |
Why?
| Gene Expression Regulation, Neoplastic | 1 | 2007 | 831 | 0.010 |
Why?
| Blood Coagulation Tests | 1 | 2002 | 20 | 0.010 |
Why?
| World Health Organization | 1 | 2002 | 50 | 0.010 |
Why?
|
|
Farrar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|